Compare ECO & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECO | TRVI |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2023 | 2019 |
| Metric | ECO | TRVI |
|---|---|---|
| Price | $52.10 | $16.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $42.00 | $21.55 |
| AVG Volume (30 Days) | 395.2K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.12% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.27 | $5.41 |
| 52 Week High | $58.45 | $16.80 |
| Indicator | ECO | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 72.54 |
| Support Level | $47.91 | $10.07 |
| Resistance Level | $52.96 | N/A |
| Average True Range (ATR) | 1.90 | 0.74 |
| MACD | 0.43 | 0.34 |
| Stochastic Oscillator | 75.21 | 96.83 |
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.